Various news about
Biogen (BIIB) present a mixed view of the company's standing in the biotech industry. On the positive side,
growth in Alzheimer's disease treatment area, with Biogen's drug
Leqembi gaining traction and achieving marketing approval in Great Britain. The company has also
raised its 2024 outlook due to strong performance and new product launches. Topline Phase 1/2 study results of an investigational drug for
Amyotrophic Lateral Sclerosis were also announced. Biogen is set to expand its rare disease pipeline by buying HI-Bio and has received approval for
Qalsody in Europe. Meanwhile, the company's efforts on cost-containment seem to be offering a boost to its profit margin. On the downside, fears about the company's future persist, with
declining revenues for multiple sclerosis therapies and higher costs associated with Aduhelm. The company has also received a setback in Europe where its Alzheimer's drug has been rejected. A class action lawsuit has also been filed against Biogen. And it has discontinued development of an experimental ALS drug. In spite of these challenges, Biogen remains a top value stock in the long term.
Biogen BIIB News Analytics from Tue, 26 Sep 2023 07:00:00 GMT to Mon, 26 Aug 2024 00:10:51 GMT -
Rating 2
- Innovation 4
- Information 3
- Rumor 3
